Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHA:600721)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Leasing and Property Services Industry	26.71M	28.40M	27.65M	22.44M	31.08M
Leasing and Property Services Industry Growth	-5.96%	2.74%	23.19%	-27.80%	-
Pharmaceutical R&D and Consistency Assessment	187.75M	203.58M	191.82M	183.77M	140.14M
Pharmaceutical R&D and Consistency Assessment Growth	-7.78%	6.13%	4.38%	31.14%	-
Clinical Trial	168.16M	148.95M	142.63M	135.89M	106.70M
Clinical Trial Growth	12.89%	4.43%	4.96%	27.35%	-
Other Income	4.82M	2.54M	4.12M	4.27M	205.58K
Other Income Growth	89.42%	-38.27%	-3.44%	1976.54%	-
Total	387.43M	383.47M	366.22M	346.37M	278.13M
Total Growth	1.03%	4.71%	5.73%	24.54%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	387.43M	-	-	-	-
Total	387.43M	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 15, 2026

Data Sources Report a data error